Hunan Nucien Pharmaceutical Co., Ltd. (SHA:688189)
China · Delayed Price · Currency is CNY 8.66
-0.09 (-1.03%)
Feb 11, 2026, 4:00 PM EST
SHA:688189 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 95.3 | 263.26 | 720.05 | 698.8 | 743.11 | 1,029 |
Other Revenue | 0.02 | 0.02 | 0.01 | 0.02 | 0.55 | 0.07 |
| 95.33 | 263.28 | 720.06 | 698.83 | 743.66 | 1,029 | |
Revenue Growth (YoY) | -76.70% | -63.44% | 3.04% | -6.03% | -27.74% | 1.47% |
Cost of Revenue | 86.41 | 129.61 | 121.53 | 117.85 | 106.77 | 106.97 |
Gross Profit | 8.92 | 133.68 | 598.53 | 580.98 | 636.89 | 922.17 |
Selling, General & Admin | 118.76 | 156.21 | 422.37 | 486.81 | 656.18 | 661.99 |
Research & Development | 49.78 | 48.81 | 74.86 | 58.16 | 78.03 | 94.04 |
Other Operating Expenses | 2.32 | 4.87 | 9.86 | 9.43 | 10.43 | 13.62 |
Operating Expenses | 375.25 | 493.59 | 594.2 | 660.57 | 853.05 | 800.21 |
Operating Income | -366.33 | -359.91 | 4.33 | -79.6 | -216.16 | 121.96 |
Interest Expense | -4.09 | -5.4 | -15.25 | -22.03 | -15.92 | -13.38 |
Interest & Investment Income | 4.77 | 6.97 | 10.77 | 16.76 | 21.45 | 15.8 |
Currency Exchange Gain (Loss) | -0.02 | -0.02 | - | -0.07 | 0.03 | 0.02 |
Other Non Operating Income (Expenses) | 0.23 | -0.09 | -0.51 | -0.3 | -3.54 | -0.49 |
EBT Excluding Unusual Items | -365.44 | -358.45 | -0.66 | -85.23 | -214.15 | 123.91 |
Impairment of Goodwill | -10.85 | -10.85 | - | -2.72 | -14.69 | - |
Gain (Loss) on Sale of Investments | -4.37 | - | -14.91 | -5.63 | - | - |
Gain (Loss) on Sale of Assets | 2.82 | 0.59 | 0.17 | - | - | 0.08 |
Asset Writedown | -23.21 | -21.14 | - | -0.02 | -2.03 | - |
Other Unusual Items | 2.34 | 1.2 | 6.25 | 19.6 | 16.08 | 10.41 |
Pretax Income | -398.69 | -388.64 | -9.14 | -74.01 | -214.79 | 134.4 |
Income Tax Expense | 8.44 | 8.64 | 1.65 | 23.61 | -32.3 | 0.12 |
Earnings From Continuing Operations | -407.13 | -397.27 | -10.79 | -97.61 | -182.48 | 134.27 |
Minority Interest in Earnings | 38.8 | 40.37 | -0.08 | 18.78 | 20.6 | -6.3 |
Net Income | -368.32 | -356.9 | -10.87 | -78.83 | -161.88 | 127.97 |
Net Income to Common | -368.32 | -356.9 | -10.87 | -78.83 | -161.88 | 127.97 |
Net Income Growth | - | - | - | - | - | 39.90% |
Shares Outstanding (Basic) | 275 | 274 | 274 | 274 | 274 | 257 |
Shares Outstanding (Diluted) | 275 | 274 | 274 | 274 | 274 | 257 |
Shares Change (YoY) | -0.65% | -0.03% | 0.03% | -0.01% | 6.66% | 25.02% |
EPS (Basic) | -1.34 | -1.30 | -0.04 | -0.29 | -0.59 | 0.50 |
EPS (Diluted) | -1.34 | -1.30 | -0.04 | -0.29 | -0.59 | 0.50 |
EPS Growth | - | - | - | - | - | 11.90% |
Free Cash Flow | -45.52 | -57.03 | 183.74 | -201.1 | -176.7 | -318.34 |
Free Cash Flow Per Share | -0.17 | -0.21 | 0.67 | -0.73 | -0.64 | -1.24 |
Dividend Per Share | - | - | - | - | - | 0.148 |
Gross Margin | 9.35% | 50.77% | 83.12% | 83.14% | 85.64% | 89.61% |
Operating Margin | -384.28% | -136.70% | 0.60% | -11.39% | -29.07% | 11.85% |
Profit Margin | -386.37% | -135.56% | -1.51% | -11.28% | -21.77% | 12.44% |
Free Cash Flow Margin | -47.75% | -21.66% | 25.52% | -28.78% | -23.76% | -30.93% |
EBITDA | -329.57 | -323.52 | 40.23 | -32.94 | -178.55 | 156.4 |
EBITDA Margin | - | -122.88% | 5.59% | -4.71% | -24.01% | 15.20% |
D&A For EBITDA | 36.76 | 36.39 | 35.89 | 46.66 | 37.61 | 34.44 |
EBIT | -366.33 | -359.91 | 4.33 | -79.6 | -216.16 | 121.96 |
EBIT Margin | - | -136.70% | 0.60% | -11.39% | -29.07% | 11.85% |
Effective Tax Rate | - | - | - | - | - | 0.09% |
Revenue as Reported | 95.33 | 263.28 | 720.06 | 698.83 | 743.66 | 1,029 |
Advertising Expenses | - | 92.62 | 331.97 | - | 0.16 | 4.57 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.